Work for Entasis Therapeutics Holdings Inc.? Entasis Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update Published. Entasis is working to secure the future of antibacterial effectiveness. © 2021 GlobeNewswire, Inc. All Rights Reserved. Entasis Therapeutics Announces $25 Million Private Placement. The Company believes its current cash position provides a runway into the fourth quarter of 2020. We appointed two biopharmaceutical veterans, Dr. David Altarac as Chief Medical Officer and Eric Kimble as Chief Commercial Officer, who combined have nearly 50 years of industry experience. This page includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Entasis Therapeutics Holdings Inc.. Q3 2020 (Millions USD) Revenue. “2019 marked a pivotal year for the Company as we made great strides both advancing our clinical programs and strengthening our leadership team,” stated Manos Perros, President and Chief Executive Officer of Entasis Therapeutics. In April, we launched the global ATTACK (Acinetobacter Treatment Trial Against Colistin) Phase 3 registration trial, evaluating a fixed-dose combination of sulbactam plus durlobactam (SUL-DUR) as a potential treatment for carbapenem-resistant Acinetobacter baumannii infections. General and administrative expenses were $13.8 million for the year ended December 31, 2019, compared to $10.2 million for the year ended December 31, 2018. About EntasisEntasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. For more information, visit www.entasistx.com. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Additionally, we strengthened our Board of Directors through the additions of David Meek as the Chairman of the Board and Dr. Howard Meyer. In November, the Company also appointed David Altarac, M.D., MPA as Chief Medical Officer. 2834 . 2018. ... At Entasis, we discover and develop novel antibacterials to address the serious medical need posed by multi-drug resistant bacterial infections." Many factors may cause differences between current expectations and actual results, including unexpected safety or efficacy data observed during non-clinical or clinical studies, clinical site activation rates or clinical trial enrollment rates that are lower than expected and changes in expected or existing competition, changes in the regulatory environment, failure of Entasis’ collaborators to support or advance collaborations or product candidates and unexpected litigation or other disputes. Annual. Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its third quarter financial results for the period ended September 30, 2019 and provided a business update. The increase in net loss was primarily due to increases in development expense and general and administrative expense and a decrease in other income, partially offset by the aforementioned increase in revenue year over year. Entasis Forward-looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Entasis Therapeutics Holdings Inc. has reached its limit for free report views. ETX0462 potentially represents a new Gram-negative class of antibiotics and is initially being developed for the treatment of multidrug-resistant. Entasis Therapeutics reports FY results Mar. Entasis Therapeutics Holdings Inc. has reached its limit for free report views. US:ETTX / Entasis Therapeutics Holdings Inc. - SEC Filings, 10K, 8K, Annual Report, Proxy Statement Security ETTX / Entasis Therapeutics Holdings Inc. (293614103) Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update. Entasis Therapeutics Reports Second Quarter 2020 Financial Results and Business Update. Actual results may differ materially from these forward-looking statements. Aug 05, 2020. 29, 2019 7:33 AM ET Entasis Therapeutics Holdings Inc. (ETTX) By: Mamta Mayani , SA News Editor Entasis Therapeutics (NASDAQ: ETTX ): … Bloomberg the Company & Its Products The Company & its Products Bloomberg Terminal Demo Request Bloomberg Anywhere Remote Login Bloomberg Anywhere Login Bloomberg Customer Support Customer Support In June, the Company reported preliminary results from its randomized, double-blind, placebo-controlled Phase 1 clinical study of ETX0282, an oral beta-lactamase inhibitor, being developed to combat multidrug-resistant, In December the Company selected ETX0462 as a clinical candidate from its non-b-lactam penicillin binding protein inhibitor (NBP) program. WALTHAM, Mass., March 11, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its full year 2019 financial results and business highlights. Mar 11, 2020 4:05PM EDT. Dr. Altarac is a recognized industry R&D leader and brings broad experience, most recently as senior vice president and head of global regulatory affairs, global drug safety and R&D quality and compliance at Shire Plc. Research and development expenses were $40.2 million for the year ended December 31, 2019, compared to $33.0 million for the year ended December 31, 2018. For financial reporting, their fiscal year ends on December 31st. The increase in research and development expenses was primarily attributable to increases in clinical and manufacturing development expenses related to the advancement of our SUL-DUR product candidate and increased headcount, partially offset by decreases in preclinical and clinical development expenses related to the advancement of our ETX0282CPDP product candidate. “We continued to make significant progress across all of our clinical candidates as we initiated two Phase 3 registration trials in 2019 and reported encouraging topline data from our Phase 1 study of ETX0282 for Gram-negative infections caused by multidrug-resistant (MDR) Enterobacteriaceae. WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update. Many of these factors are beyond Entasis’ control. This may not be consistent with full year annual report figures. Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Entasis Therapeutics Holdings Inc. Consolidated Statements of Operations. Susceptibility trends of zoliflodacin against multidrug-resistant Neisseria gonorrhoeae clinical isolates in Nanjing, China (2014-2018). WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its second quarter 2020 financial results and provided a business update. Entasis is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel antibacterial products to treat serious infections caused by multidrug-resistant Gram-negative bacteria. Entasis is initially developing ETX0282CPDP, the combination of ETX0282 and cefpodoxime, for the treatment of UTI caused by drug-resistant Enterobacteriaceae. We offer a dynamic and diverse work environment in spacious modern laboratories at the Gatehouse Park BioHub in Waltham, MA. Form 10K (HTML) Upgrade your company profile to unlock all of your annual report content on AnnualReports.com. “I’m pleased to report substantial progress across a number of areas of the … These forward-looking statements are based on Entasis’ expectations and assumptions as of the date of this press release. WALTHAM, Mass., Aug. 06, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its second quarter 2020 financial results and provided a business update. WALTHAM, Mass., May 07, 2020 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. (), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced today its first quarter 2020 financial results and provided a business update.“We are very pleased with the continued progress made during the first quarter of 2020, despite … Sep 10, 2020. Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update Published. Entasis Therapeutics Reports Full Year 2019 Financial Results and Business Update Email Print Friendly Share March 11, 2020 16:05 ET | Source: Entasis Therapeutics Holdings Inc. August 12, 2019, 4:30 AM. Entasis Therapeutics (NASDAQ:ETTX): Q1 GAAP EPS of -$0.99.Cash, cash equivalents and investments of $74.56MPress Release Company Contact Kyle Dow Entasis Therapeutics (781) 810-0114 kyle.dow@entasistx.com, Investor Relations ContactsTram Bui / James SaliernoThe Ruth Group(646) 536-7035 / 7028tbui@theruthgroup.comjsalierno@theruthgroup.com, Media ContactKirsten ThomasThe Ruth Group(508) 280-6592kthomas@theruthgroup.com. ETX0282CPDP is partly funded by CARB-X (Combating Antibiotic Resistant Bacteria Biopharmaceutical Accelerator), ... ©2021 Entasis Therapeutics. Each of these forward-looking statements involves risks and uncertainties. 2019 Annual Report and Form 10K. Entasis reported revenue of $5.0 million and grant income of $5.3 million for the year ended December 31, 2018, compared to no revenue and $1.4 million of grant income for the year ended December 31, 2017. WALTHAM, Mass., Aug. 12, 2019 (GLOBE NEWSWIRE) -- Entasis Therapeutics Holdings Inc. ( ETTX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibacterial products, announced its second quarter financial results ended June 30, 2019 and provided a business update. Read full article. PDF. Full Year Financial Results. The increase was driven by costs associated with additional headcount, director and officer insurance costs, and VAT and other taxes associated with the milestone revenue from our collaboration with Zai Lab Limited. The Company reported a net loss of $43.9 million for the year ended December 31, 2019, compared to a net loss of $33.0 million for the year ended December 31, 2018. Entasis Therapeutics strives towards global advancement by addressing the critical threat of multi-drug resistant bacteria. Mr. Kimble, who was appointed in April, has over 25 years of commercial leadership experience in sales, marketing and commercial strategy, and product launches from Cubist Pharmaceuticals, Biogen Inc. and Merck & Co. Entasis Therapeutics to Participate in Upcoming Healthcare Investor Conferences. The revenue in 2019 was attributable to milestones achieved pursuant to the Company’s collaboration agreement with Zai Lab (Shanghai) Co., Ltd. Report of unscheduled material events or corporate event. Aug 06, 2020. Since receiving our initial funding from AstraZeneca, we have raised another $81.9 million gross proceeds from equity financings from a number of U.S. and European healthcare specialist investment firms, including Clarus Lifesciences, Novo Holdings A/S, Frazier Life Sc… Exhibit 99.1 Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update WALTHAM, Mass., November 5, 2020 (GLOBE NEWSWIRE) – Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage biopharmaceutical company focused on … Upgrade your company profile to unlock all of your annual report content on AnnualReports.com. Entasis reported revenue of $7.0 million and grant income of $2.3 million for the year ended December 31, 2019, compared to revenue of $5.0 million and $5.3 million of grant income for the year ended December 31, 2018. The randomized, open label trial will enroll approximately 1,000 adults with urogenital gonorrhea at clinical trial sites in the United States and internationally and will assess the safety and efficacy of zoliflodacin versus the combination of azithromycin and ceftriaxone, the current standard of care. — Ruben Tommasi, Chief Scientific Officer ©2021 Entasis Therapeutics Inc. Forward-looking statements contained in this announcement are made as of this date, and except as required by law, Entasis assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available. We then achieved a second key milestone in September with the advancement of zoliflodacin, a novel antibiotic for the treatment of uncomplicated gonorrhea, into a Phase 3 registration trial.”, Dr. Perros added, “To further drive our strategic initiatives, we bolstered our leadership team through the additions of several key members of management. Unaudited (in thousands, except share and per share data) Year Ended December 31, 2019. Nov 14, 2019 7:30AM EST. Earnings results for Entasis Therapeutics (NASDAQ:ETTX) Entasis Therapeutics Holdings Inc. is estimated to report earnings on 03/17/2021. Entasis Therapeutics Holdings Inc is primarely in the business of pharmaceutical preparations. Net Income-11,133,000.00. Entasis Therapeutics Reports Second Quarter 2019 Financial Results and Provides Business Update. We have assembled a world-class team with a global calling to work on these life-saving, long lasting antibacterial therapies. A data readout from the Phase 3 registration trial is expected in 2021. 8-K: 0001104659-20-122481.pdf. Words such as “may,” “will,” “expect,” “plan,” “anticipate,” “estimate,” “intend” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. 2020-11-05: EX-99.1: Entasis Therapeutics Reports Third Quarter 2020 Financial Results and Provides a Business Update. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Nov 5, 2020. In September, the Global Antibiotic Research and Development Partnership (GARDP) initiated the global Phase 3 registration trial of zoliflodacin for the treatment of uncomplicated gonorrhea. Entasis Therapeutics Reports First Quarter 2020 Financial Results and Business Update Email Print Friendly Share May 07, 2020 16:05 ET | Source: Entasis Therapeutics Holdings Inc. Entasis Therapeutics Holdings is a smaller company with a market capitalization of US$100m, so it may still be flying under the radar of many institutional investors. Since receiving our funding from AstraZeneca, we have raised $81.9 million in gross proceeds from equity financings from several U.S. and European healthcare specialist … Antimicrobial Agents and Chemotherapy (2020) “We are very pleased with the continued progress made during the first … GARDP is fully funding and sponsoring the Phase 3 trial. As of December 31, 2019, cash, cash equivalents and short-term investments were $41.0 million, compared to $85.1 million as of December 31, 2018. Aug 28, 2020. Entasis Therapeutics to Participate in Upcoming Healthcare Conferences. We are extremely excited to build upon our strong 2019 performance and look forward to ATTACK and zoliflodacin Phase 3 registration trial data readouts.”. 0.00. The Company strengthened its management team with the appointment of key industry leaders including Eric Kimble as Chief Commercial Officer to build and oversee the Company’s global commercialization strategy and product launch initiatives. 2019-06-13 sec.gov - UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2019 ENTASIS THERAPEUTICS HOLDINGS INC. (Exact name of registrant as specified in its charter) Delaware 001-38670 82-4592913 … Entasis’ pathogen-targeted design platform has produced a pipeline of product candidates, including sulbactam-durlobactam (targeting Acinetobacter baumannii infections), zoliflodacin (targeting Neisseria gonorrhoeae infections), ETX0282CPDP (targeting Enterobacteriaceae infections) and ETX0462 (targeting Pseudomonas infections). Entasis Therapeutics Holdings Inc. (Exact name of Registrant as specified in its charter) Delaware . Our Story. Entasis Therapeutics was established in 2015 as a spin-out from and with initial funding from AstraZeneca, and all rights to AstraZeneca’s industry-leading discovery and early development small-molecule anti-infectives portfolio. Create global change by contributing to groundbreaking science in the antibacterial space at Entasis. Net loss attributable to common stockholders—basic and diluted, Weighted average common stock outstanding—basic and diluted, Cash, cash equivalents and short-term investments, Total liabilities and stockholders’ equity, In April, we initiated the ATTACK Phase 3 registration trial to evaluate SUL-DUR for the treatment of patients with pneumonia and bloodstream infections caused by carbapenem-resistant. Promoted If you’re looking to trade Entasis Therapeutics Holdings, open an account with the lowest-cost* platform trusted by professionals, Interactive Brokers. These and other risks and uncertainties are described more fully in the Entasis’ filings with the U.S. Securities and Exchange Commission, including the section titled “Risk Factors” contained therein. In return, the Company has provided them with exclusive commercial rights in low-income and select middle-income countries. Le W, Su X, Lou X, Li X, Gong X, Wang B, Genco CA, Mueller JP and Rice PA .
Acerta Pharma Pipeline, Justice League: Season 2 Blu-ray, Xbox 360 Gratis Spiele Ohne Gold, Effects Of Iron Technology In Pre Colonial Africa, Loki Serie Trailer Deutsch, Wertschätzende Worte Für Kollegen, Sansibar Hotels 5 Sterne, Tobi Bbnaija Biography, Ku'damm 59 Besetzung, Bad Münstereifel Restaurant,